Oakbrook Investments LLC increased its stake in shares of Endo International PLC (NASDAQ:ENDP) by 8.2% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 17,100 shares of the company’s stock after buying an additional 1,300 shares during the period. Oakbrook Investments LLC’s holdings in Endo International PLC were worth $191,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. First Quadrant L P CA bought a new position in shares of Endo International PLC during the first quarter valued at approximately $24,556,000. OppenheimerFunds Inc. boosted its position in shares of Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after buying an additional 1,857,678 shares during the period. Norges Bank bought a new position in shares of Endo International PLC during the fourth quarter valued at approximately $26,929,000. Bank of New York Mellon Corp boosted its position in shares of Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in shares of Endo International PLC by 685.0% in the first quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock valued at $6,185,000 after buying an additional 483,545 shares during the period. 92.83% of the stock is owned by hedge funds and other institutional investors.
Shares of Endo International PLC (NASDAQ:ENDP) traded down 3.36% during trading on Tuesday, hitting $10.65. The stock had a trading volume of 3,440,816 shares. The company’s 50 day moving average price is $11.47 and its 200 day moving average price is $11.78. The company’s market capitalization is $2.38 billion. Endo International PLC has a 52 week low of $9.70 and a 52 week high of $24.93.
Endo International PLC (NASDAQ:ENDP) last announced its earnings results on Tuesday, May 9th. The company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.13. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the previous year, the business earned $1.08 EPS. The company’s revenue was up 7.7% compared to the same quarter last year. Analysts predict that Endo International PLC will post $3.54 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/01/oakbrook-investments-llc-buys-1300-shares-of-endo-international-plc-nasdaqendp.html.
ENDP has been the subject of several recent research reports. Mizuho reissued a “buy” rating and set a $18.00 price target (up from $17.00) on shares of Endo International PLC in a research report on Thursday, April 13th. Zacks Investment Research raised Endo International PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, May 2nd. Canaccord Genuity set a $14.00 price target on Endo International PLC and gave the company a “hold” rating in a research report on Monday, May 1st. BMO Capital Markets reissued a “hold” rating and set a $15.00 price target on shares of Endo International PLC in a research report on Monday, May 1st. Finally, Vetr raised Endo International PLC from a “strong sell” rating to a “sell” rating and set a $11.34 price target for the company in a research report on Wednesday, May 17th. Three equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $17.33.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Want to see what other hedge funds are holding ENDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endo International PLC (NASDAQ:ENDP).
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.
